Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613650 · ClinicalTrials.gov registry record · Phase 1
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
A Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02613650: Completed Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer, sponsored by University of Utah.
NCT02613650 is a Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer that has completed, run by University of Utah. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02613650, a Phase 1 study of Advanced KRAS Positive Metastatic Colorectal Cancer, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination
Conditions Studied
Interventions
- DRUG MEK162 and mFOLFIRI
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-08-19 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
What the finished NCT02613650 record still lists
NCT02613650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Advanced KRAS Positive Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MEK162 and mFOLFIRI is the first listed.
NCT02613650 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT02613650 about?
NCT02613650 is a clinical study titled "A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers". This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination
What is the current status of trial NCT02613650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-08-19. Estimated completion is 2022-12-21.
What conditions does trial NCT02613650 study?
This clinical trial studies the following conditions: Advanced KRAS Positive Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT02613650?
The interventions under investigation include: MEK162 and mFOLFIRI (DRUG).
Who is sponsoring clinical trial NCT02613650?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02613650 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02613650's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI